Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18645951 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | April 2024 | October 2024 | Allow | 6 | 1 | 1 | No | No |
| 18645961 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | April 2024 | October 2024 | Allow | 6 | 1 | 1 | No | No |
| 18645942 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | April 2024 | October 2024 | Allow | 6 | 1 | 1 | No | No |
| 18641205 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | April 2024 | February 2025 | Allow | 10 | 1 | 0 | No | No |
| 18438342 | COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | February 2024 | December 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18500970 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | November 2023 | July 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18499857 | ADOPTIVE CELL TRANSFER AND ONCOLYTIC VIRUS COMBINATION THERAPY | November 2023 | June 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18385879 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | October 2023 | August 2024 | Allow | 10 | 2 | 1 | Yes | No |
| 18462340 | RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE | September 2023 | October 2024 | Allow | 13 | 0 | 0 | No | No |
| 18242025 | ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME | September 2023 | March 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18339553 | METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODS | June 2023 | April 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18329441 | NEUTRALIZING ANTIBODY IMMUNOASSAYS | June 2023 | May 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18328403 | Compositions for Booster Vaccination Against Dengue | June 2023 | July 2025 | Abandon | 26 | 2 | 0 | Yes | No |
| 18327882 | CORONAVIRUS VACCINE | June 2023 | September 2023 | Allow | 4 | 3 | 0 | Yes | No |
| 18142988 | AAV CAPSID PRODUCTION IN INSECT CELLS | May 2023 | April 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18308934 | HYPERIMMUNIZED EGG PRODUCT FOR TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION | April 2023 | April 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18098949 | SAPONIN PURIFICATION | January 2023 | October 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 18085110 | VIRUS PURIFICATION AND FORMULATION PROCESS | December 2022 | January 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18052178 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | November 2022 | January 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18051819 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | November 2022 | January 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17970036 | COMPOSITIONS AND METHODS FOR DELIVERY OF AAV | October 2022 | December 2024 | Allow | 26 | 1 | 0 | No | No |
| 18046243 | Compositions and Administration of Chimeric Glycoprotein Lyssavirus Vaccines for Coverage Against Rabies | October 2022 | July 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17869306 | HCoV IMMUNOGENIC BOOSTER COMPOSITION FOR IMPROVING IMMUNITYAGAINST SARS-COV-2 INFECTION | July 2022 | October 2024 | Allow | 27 | 1 | 0 | Yes | No |
| 17857303 | Virus-Like Particle Conjugates | July 2022 | January 2025 | Allow | 31 | 1 | 0 | No | No |
| 17856774 | MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS | July 2022 | October 2024 | Allow | 27 | 1 | 0 | Yes | No |
| 17851492 | SAPOVIRUS VACCINES | June 2022 | June 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17839401 | HUMAN CYTOMEGALOVIRUS VACCINE | June 2022 | October 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17837294 | COMBINATION IMMUNOTHERAPIES FOR TREATMENT OF CANCER | June 2022 | April 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17709599 | COVALENTLY MODIFIED ANTIGENS FOR IMPROVED IMMUNE RESPONSE AND/OR STABILITY | March 2022 | July 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17575462 | USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS | January 2022 | April 2025 | Allow | 40 | 3 | 0 | Yes | No |
| 17613602 | PHARMACEUTICAL COMPOSITIONS TO ENHANCE PHAGOCYTOSIS WITHOUT INFLAMMATION | November 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17613011 | DRUG-RESISTANT INFLUENZA VIRUS STRAINS | November 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17610026 | ATTENUATED YELLOW FEVER VIRUS AND USES THEREOF FOR THE TREATMENT OF CANCER | November 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17609217 | INACTIVATED VIRUS COMPOSITIONS AND ZIKA VACCINE FORMULATIONS | November 2021 | June 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17607213 | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF | October 2021 | September 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17512246 | SYSTEMS AND METHODS FOR ULTRA-SPECIFIC AND ULTRA-SENSITIVE NUCLEIC ACID DETECTION | October 2021 | March 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17487690 | MULTI-SPECIFIC ANTIBODIES FOR CROSS-NEUTRALIZATION OF MULTIPLE FILOVIRUS GLYCOPROTEINS | September 2021 | July 2024 | Allow | 34 | 1 | 1 | No | No |
| 17442871 | IMMUNOCHROMATOGRAPHIC ASSAY METHOD, AND TEST STRIP USED IN SAID IMMUNOCHROMATOGRAPHIC ASSAY METHOD | September 2021 | March 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17478537 | Compositions and Methods for Dengue Virus Chimeric Constructions in Vaccines | September 2021 | May 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17404143 | Filovirus Consensus Antigens, Nucleic Acid Constructs and Vaccines Made Therefrom, and Methods of Using Same | August 2021 | October 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17401079 | Rapid Viral Diagnostic Test | August 2021 | April 2025 | Abandon | 44 | 2 | 1 | No | No |
| 17386644 | VIRAL VECTOR ASSAY AND VECTOR | July 2021 | November 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17385416 | THERMAL INACTIVATION OF ROTAVIRUS | July 2021 | March 2025 | Abandon | 44 | 2 | 1 | Yes | No |
| 17372044 | BOVINE HERPESVIRUS TYPE 1 (BOHV-1) VECTOR AGAINST BOVINE RESPIRATORY DISEASE COMPLEX | July 2021 | January 2025 | Allow | 42 | 2 | 0 | No | No |
| 17357368 | VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE STRANDED RNA VIRUSES | June 2021 | February 2025 | Abandon | 43 | 3 | 1 | Yes | No |
| 17325149 | METHOD AND COMPOSITION FOR AMELIORATING AND ABATING SYMPTOMS RESULTING FROM RHEUMATOID ARTHRITIS, FIBROMYALGIA, AND CHRONIC PAIN OF UNKNOWN ORIGIN | May 2021 | August 2025 | Abandon | 51 | 3 | 0 | No | No |
| 17246364 | VIRAL SEROLOGY ASSAYS | April 2021 | July 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17232751 | NANO-SATELLITE COMPLEXES | April 2021 | October 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17276788 | CORONAVIRUS VACCINE | March 2021 | November 2024 | Allow | 44 | 1 | 0 | Yes | No |
| 17172300 | COMPOSITIONS IMMUNOGENIC AGAINST SARS CORONAVIRUS 2, METHODS OF MAKING, AND USING THEREOF | February 2021 | January 2025 | Abandon | 47 | 4 | 1 | No | No |
| 17266049 | RECOMBINANT BIOLOGICALLY CONTAINED FILOVIRUS VACCINE | February 2021 | January 2025 | Allow | 47 | 4 | 0 | Yes | No |
| 17264370 | METHODS AND COMPOSITIONS TO DETECT MICROBES AND VIRAL PARTICLES | January 2021 | August 2025 | Abandon | 54 | 2 | 1 | No | No |
| 16972077 | ANTIBODIES OR ANTIBODY-FRAGMENTS THEREOF TARGETING ALPHAVIRUSES, AND COMPOSITIONS AND METHODS COMPRISING SAME | December 2020 | August 2024 | Allow | 45 | 3 | 1 | Yes | No |
| 17059882 | TARGETING P18 FOR mTOR-RELATED DISORDERS | November 2020 | September 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17097687 | METHOD FOR DETERMINING THE SENSITIVITY OF A BACTERIAL STRAIN TO A BACTERIOPHAGE | November 2020 | December 2024 | Allow | 49 | 4 | 0 | Yes | No |
| 17047611 | BACTERIOPHAGE COMPOSITIONS | October 2020 | February 2025 | Allow | 52 | 3 | 1 | No | No |
| 17040455 | IMMUNOSUPPRESSIVE MATERIALS AND RELATED METHODS | September 2020 | August 2024 | Allow | 47 | 1 | 1 | No | No |
| 16981197 | SURFACE FUNCTIONALISED MATERIALS FOR SAMPLING BIOLOGICAL MOLECULES | September 2020 | February 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 16976220 | ATTENUATED FLAVIVIRUSES | August 2020 | August 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 16755257 | MAYARO VIRUS CONSENSUS ANTIGENS, DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MAYARO VIRUS, AND COMBINATIONS THEREOF | April 2020 | September 2024 | Allow | 53 | 6 | 1 | Yes | No |
| 15682341 | METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIES | August 2017 | November 2024 | Abandon | 60 | 9 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner CHEN, STACY BROWN works in Art Unit 1671 and has examined 31 patent applications in our dataset. With an allowance rate of 54.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner CHEN, STACY BROWN's allowance rate of 54.8% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHEN, STACY BROWN receive 2.26 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHEN, STACY BROWN is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +54.6% benefit to allowance rate for applications examined by CHEN, STACY BROWN. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.